To further investigate the role of AKT/NF-κB signaling in regulating GLI1, we utilized GSK690693, a PI3K/AKT inhibitor, and QNZ, a selective NF-κB inhibitor, while silencing AKT/NFKB1 in SDF-1α pretreated GBM cells. This evidence concerns the gene CXCL12 and glioblastoma.